FINWIRES · TerminalLIVE
FINWIRES

HKG:6622

4 stories mentioning HKG:6622Updated just now

Every FINWIRES story that references HKG:6622, newest first.

Asia

Zhaoke Ophthalmology's Vision Loss Drug Meets Primary Endpoint in Phase II Study

Zhaoke Ophthalmology's (HKG:6622) carbachol and brimonidine tartrate ophthalmic solution met its prespecified primary endpoint in a phase II trial in China.The treatment was well tolerated with a favorable safety profile, according to a Friday Hong Kong bourse filing.The drug is an eye drop formulation designed to restore near vision loss due to presbyopia.The company intends to discuss advancing a phase III study with China's National Medical Products Administration.

HKG:6622
Asia

Zhaoke Ophthalmology Wins Macau Approval for Presbyopia Drug

Zhaoke Ophthalmology's (HKG:6622) presbyopia drug YUVEZZI has been approved by Macau's Pharmaceutical Administration Bureau for the treatment of age-related near vision loss, according to a Monday Hong Kong bourse filing.The company said it plans to seek access for the drug under the Hong Kong-Macau Medicine and Equipment Connect program to support its early clinical use in the Greater Bay Area.

HKG:6622
Asia

Zhaoke Ophthalmology's Application for Children's Myopia Drug Accepted in Australia

Zhaoke Ophthalmology's (HKG:6622) registration application for Atropine Sulfate Eye Drops was accepted for evaluation by the Therapeutic Goods Administration of Australia, according to a Monday Hong Kong bourse filing.The drug is for slowing the progression of myopia in children.

HKG:6622
Asia

Zhaoke Ophthalmology Grants Commercialization Licence for Dry Eye Drug in Indonesia

Zhaoke Ophthalmology (HKG:6622) entered into a distribution and supply agreement with Erlangga Edi Laboratories to commercialize CsA Ophthalmic Gel in Indonesia, according to a Friday Hong Kong bourse filing.Under the agreement, the ophthalmic drug maker granted Erlangga exclusive rights to register, import, promote, distribute, market, and sell the dry eye disease drug in Indonesia.The firm will receive an upfront payment and additional milestone payments based on specific achievements.

HKG:6622

Track with the FINWIRES app suite

FolioX
FolioX
Track HKG:6622 in your portfolio
WheelAI
WheelAI
Analyze HKG:6622 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on HKG:6622